Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2025
Reimbursement for oral Fabry disease drug Galafold expanded to first-line treatment
1 August 2025 - Handok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line ...
Posted by Michael Wonder on 01 Aug 2025
Norgine welcomes PBS listing in Australia of Ifinwil (eflornithine) for patients with high-risk neuroblastoma
1 August 2025 - Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having ...
Posted by Michael Wonder on 31 Jul 2025
Schedule of Pharmaceutical Benefits - 1 August 2015
1 August 2025 - The August 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2025
New Zealand Pharmaceutical Schedule - 1 August 2025
1 August 2025 - - The August 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in ...
Posted by Michael Wonder on 30 Jul 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx for hidradenitis suppurativa (
23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec. ...
Posted by Michael Wonder on 20 Jul 2025
New and expanded cheaper medicines for severe and life-threatening conditions
20 July 2025 - Australians with post-transplant cytomegalovirus, breast, bile duct and urothelial cancer now have access to new and expanded ...
Posted by Michael Wonder on 16 Jul 2025
BeOne bets Tevimbra will beat rivals to PD-1 reimbursement in Korea
15 July 2025 - BeOne Medicines (formerly BeiGene) is doubling down on Korea’s immunotherapy market with an early access push ...
Posted by Michael Wonder on 15 Jul 2025
Vertex announces broad reimbursement agreement with NHS England for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) an innovative once daily CFTR modulator for the treatment of cystic fibrosis
14 July 2025 - All eligible people with cystic fibrosis in England can now benefit from this medicine - ...
Posted by Michael Wonder on 05 Jul 2025
Quebec implements public reimbursement of Pluvicto - a defining milestone for radioligand therapy in Canada
3 July 2025 - Pluvicto now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA ...
Posted by Michael Wonder on 03 Jul 2025
Bayer's Adempas gets insurance coverage in Korea 11 years after approval
21 May 2025 - The pulmonary arterial hypertension medicine Adempas (riociguat) will be covered by national health insurance starting next ...
Posted by Michael Wonder on 03 Jul 2025
Top level push for taxpayer funding of weight loss drugs gathers pace
3 July 2025 - Pharma giants are sweating on the results of a federal government request for guidance on adding weight ...
Posted by Michael Wonder on 02 Jul 2025
Calls for 'missing piece' menopause drug to be added to the PBS
2 July 2025 - A key treatment which could help around one million middle-aged Australian women remains unaffordable to many ...
Posted by Michael Wonder on 02 Jul 2025
Life-saving breast cancer drug now cheaper thanks to expansion of the PBS
1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...
Posted by Michael Wonder on 01 Jul 2025
New Zealand Pharmaceutical Schedule - 1 July 2025
1 July 2025 - The July 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Jul 2025
Schedule of Pharmaceutical Benefits - 1 July 2025
1 July 2025 - The July 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...